Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How does a CEO allay concerns about insider trading on the prospect for a buyout!/(JV)? He does it by openly stating that his company isn't positioned to provide the deserved market wherewithal to fully support the widespread adoption & use of his company's product. He then further qualifies his expectations by assuring audiences that the company no longer needs to raise funds to support the development of any of its products. All of this begs the question "Will we even see the (undoubtedly finished) 10K before an overshadowing announcement is made?"
Sounds reasonable. No one would be surprised to learn, however, which financial entity actually controls the 212 app or how easy it was for them to game trading advantages of listed holding companies which it financed on 212 & similarly controlled platforms when monetary policy & money supply favored loose OS structure.
If IQST does not tighten its share structure within the next few months, then we will know that Apollo has decided not to prioritize its growth by the quick & full exercise of its"master fund"
Even before the offerings, share structure has proven to be too loose for a recession. During the last year IQST has shed 75% of its value & 90% iover the last 22 months. Things will not improve until share structure is tightened to match market conditions. A reverse split is the company's only option.
There is no real stock price buoyancy difference between your claimed 166 million OS & the discounted ~185 million total I am justifying the need for a RS with.
Or maybe the involved trading houses low-level employees are too inflexible to ply their methods with other emerging companies in a more difficult trading environment, so they intend to cling desperately to sham pennies that will starve IQST of real opportunities.
You do know that when I have time later I will post the amended table & schedule right? & be discussing market positioning & lessons from ALPP (which is also facing a RS)
A RS is not a scam when it is done by a company projecting 9 figure earnings to address its need for share price traction to gain access to institutional investors & escape flim flam sourcing for working capital.
So you are de-emphasizing the discount formula which allows Apollo to obtain shares at about .16 for the current price with scheduled pay $480,000 by dates totalling 3.8 million that I am adding to the 10 million sell at best price shares being offered by. IQST.
A RS by year end or to start 2023 likely favors $IQST shareholders if the company can properly stack news. The recent offering will increase OS by about 32 million shares & provide the company about 6 million in total cash (It is practical for Apollo to exercise all option conditions now & for the company to sell shares on reported consistencies). Furthermore, the release of fantastic news by a company with 190 million OS that is projecting/substantiating 90 million in revenue will not move share price more than a nickel because of the necessary selling & other investment market pricing pressures. Nevertheless, we can feel safe in knowing that the continuing .24-.29 price range is the bottom & is an excellent buying opportunity for those counting on a 1/4 or 1/5 RS to allow the best expected news to make the share price sustainingly exceed Nasdaq compliance.
Any prognostication about the pre-BLA that alleges CVM investor relations as a source is an act of deception relying upon presumptions about the 60 day calendar for an agreed & approved scheduling of the pre-BLA by the FDA. Included within the 60 day pre-BLA calendar is a 21 day window for the scheduled meeting notice letter to arrive. As such, it is wrong to discount CVM's pre-BLA occurring during 2022 until after Thanksgiving. Moreover, investor relations would never be made party to negotiations between CVM & the FDA until SEC reporting required material events happen, because leaks are too litigiously expensive.
Your $12B expectation is ridiculous & unrealistic. The wide use window for Multikine isn't long enough. Cutting edge understanding of cancer cellular dynamics are currently finding expression in clinical trials. In addition, it will take time to erode Keytruda's market share (after additional small scale alternative use clinical trials for Multikine). I expect an accepted buyout offer to ranger from 3-6B.
Does no Pre-BLA = Buyout? Does the prospect of ownership change unnecessarily complicate FDA review of major filings? It is reasonable to expect that any BP would want to minimize time costs between purchase & FDA review
FrugalNorwegian's published clickbait opinions rely as much upon innuendo of having insider sources as those of stinky fish when he prognosticates self-interested outcomes from invented "nuggets". While FN offers reasonably consistent speculation upon public information, stinky muddles inconsistencies to fit trading house portfolio strategies.
Many here have no doubt concluded that the interactions between these message board posters shrouds an actual personal & collegial relationship whereupon they rely upon each other's posting to qualify their own status as prime & to conceal their actual purposes.
FrugalNorwegian's clickbait published opinions rely as much upon innuendo of having insider sources as those of stinky fish when he prognosticates self-interested outcomes from invented "nuggets". While FN offers reasonably consistent speculation upon public information, stinky muddles inconsistencies to fit trading house portfolio strategies.
How likely is it that the announced scheduling of the Pre-BLA occurs tomorrow only to have its impact upon stock price tempered by Fed Policy announcements? At the moment, it is reasonable for the share price to reflect the risk of CVM not being given a Pre-BLA. What is the expected value of having a scheduled Pre-BLA on share price? How much will fed policy discount market expectations? Are an immediate run to $17 & thereafter a continuing $17 pricing median through the Pre-BLA meeting (with a modest facility validation/ full employment related small offering included) unreasonable expectations because of money supply tightening?
Will facility validation be a ceremonious ribbon cutting event for Dr. Renee Wegrzyn & ARPA-H?
Requesting a Pre-BLA isn't difficult. I rxpect notice of its valuable scheduling to be given by mid-September 2022. On this timeline, an informing Pre-BLA will occur by mid-November & the BLA could occur as soon as February 2023.
New York, NY, June 01, 2022 (GLOBE NEWSWIRE) -- iQSTEL, Inc. (OTCQX: IQST) today announced entering into an exclusive, non-binding letter-of-intent (LOI) whereby, for the purposes of an intended acquisition, the company will conduct due diligence on 2,300 miles of fiber-optic network located in America.
iQSTEL has been in discussions with the target acquisition over the past two years first announcing a potential partnership in May of 2021.
The acquisition would accelerate iQSTEL’s entry into the 5G marketplace, expected to reach $700 billion by 2025.
Following a 90-day due-diligence period, iQSTEL is expected to make an offer for the acquisition of 100% of the capital stock of the company that owns the fiber-optic network.
It is about day 90 on the FIber Optic LOI
more background
https://www.globenewswire.com/news-release/2020/03/10/1997799/0/en/iQSTEL-Uses-Its-25M-Acquisition-Funding-Towards-the-Offer-for-a-2-300-Mile-Central-American-Fiber-Optic-Network-Company.html
Awaiting post-breakout announcement of swing shares being bought at 3.38 & 3.60 early this morning
$5 is more likely tomorrow than $3
on Market Efficiency & Regulatory Responsiveness
Submissions & corrections are active & ongoing realtime processes on the Protocol Registration and Results System (PRS) iHow to Submit Your Results . For CVM, this has been 150+ days. Calendar updating of changes to its submission markings provides time-vaue denotations for the interested public. The quick updating of the latest submission does (according to the 21, 11, 5, & 0 day edit windows on their submission's release for review by NLM) mean that the submission will quickly be stamped by the First Submitted that met QC criteria dating (if not already).
My assessment of the process stands corrected. A closer look at your misrepresentation of data points does provide a clearer view of the QC process for all.
For Multikine we know:
Results First Submitted July 19. 2022
We Don't Know:
Results First Submitted that Met QC Criteria :
Results First Posted
[How does the Met QC criteiria date affect the 30 day response calendar, given the 32 day difference from your linked second example]
Your Misrepresentations
Submitted 8/27 posted 8/29
Submitted 8/14, posted 8/28
Submitted 12/10 poste 1/4
!0 Q out $28 million in cash & cash equivalents
You can't cite a verifiable example of QA responding quicker for successful submissions. In fact, to allege such implies that the submission review process is not standardized.
Either the return date will appear on CT.gov early tuesday or the Data will be available by wednesday (day 30)
I'd like to see the incessant pattern of midweek news & thursday shareholder letters the following week broken with money related news on a Monday to add excitement to the week by inflaming expactations for midweek whetting.
There is a consensus desire within university communities to switch their street legal smaill vehicle fleets from gas to electric (particularly for their Parking & Transit departments). Similar opportunities exist in corporate & municipal settings.
The winners under prevailing market sentiments are countervailing beacons. Ongoing profit taking & panic selling spurred by inflation, though important, are marginal variables within a system well served by the broad demand inducing regulatory framework governing error prone central banks.
If we were discussing ILUS, WPUR, PMPG, ALYI, or etc, then I'd fully agree that the fortunes of shareholders & the companies themselves will inevitably be affected by negative market sentiments. We are, however, talking about IQST, an essentially profitable & solidly positioned emerging telecom with market responsive technology & a diversifying array of products & services who simply needs to boldly assert & fearlessly interject itself into every viable corner to command greater reception.
Why has management eroded investor confidence by connoting an association between global market conditions & stock performance when those conditions have had no bearing upon the company's forecasted performance? Is a myopic 10-20% increase in stock compensation really worth the trouble when an opportunity to make up the difference presents itself annually?
What role has the market trends ignoring "names & numbers" public relations demands of some stockholders deterrred tthe company from unabashedly increasing its public profile by all legitimate means in order to expand its shareholder base as an offset to those ongoing trends? How much has the unnecessary silence contributed to extending product & customer timeline uncertainties?
What is "soon"? From may 11th PR..".Our IoTSmartGas/Tank has been deployed with a Fortune 500 chemical corporation customer. We expect to soon announce the results of this first deployment and then begin a global sales and marketing campaign.
IQST is a recession proof Cash Cow. Management discussion of fundraising next year is likely referencing the $60 million from the IBank. In the meantime, I think we can expect that high margin Global Money One revenues are currently being generated & will finally be reflected in the 2nd quarter's balance sheet ( & eye poppingly in subsequent quarters).
It would be nice if National Library of Medicine disclosed that Covid has created a backlog for its Quality Control services. It there were no backlog it would be proper to expect QC to fully utilize the 30 day calendar so as to avoid future time costs associated with duplication. As it stands now, all we know for certain is that submissions are being strictly dated on an exact 28 day schedule. We do not know if data has received any Quality Control comments (though it is unlikely CVM would have not addressed all queries from NLM QC as soon as they were presented.
Russell Index MicroCap addition list: the June 3rd preliminary list inclusion of Gold Matrix Group Inc GMGI with its market cap on May 6th of 122 million indicates that Cel-Sci's May 6th Market Cap of 132 million has predetermined its inclusion in one of the upcoming Friday updates to that list.
isn't the BLA filing only awaiting certification of the upgraded facility? Can't we also speculate that the Annual Meeting is being held at the hotel conference room because the imminent certification would risk violation if the meeting were held on location?
I suspect institutional & retail investors will respond appropriately to the entrusting degree of $CVM data confidence & managerial effectiveness demonstrates by maximizing the extent that posted clinicaltrials.gov results availability corresponds to the release of abstracts by ASCO.
Once data is posted nothing prohibits $CVM from immediately submitting multikine's FDA application. I expect new details to emerge daily up to the ASCO & perhaps a little well deserved bombast at the annual meeting on Monday June 13th, 2022. While I do not expect share price to be as pretty as it has been in the recent past, it will have an unfading shine.
iQSTEL needs to solidify the credibility of its IOT division by validating the results of its SmartTank with a contract extension/expansion with the Fortune 500 company. Otherwise, the questions surrounding the future contribution of the division to the both the value of EVOSS & the companies bottom line will become insurmountable. The sooner the company can provide positive IOT news the better it will be for their plans to overcome IOT's discount impact questions on share price with trade price multiple & prospective non telecom revenues.
In short, APO is betting $500,000 that its option for 4-8 million shares of $IQST will be worth more than $2/ share on September 30th. The bet suggests an expectation that the share price will really be more than $2.07 for 8 million shares & more than $2.13 for 4 million.
Every stock option has an exercise price, also called the strike price, which is the price at which a share can be bought. In the US, the exercise price is typically set at the fair market value of the underlying stock as of the date the option is granted, in order to comply with certain requirements under US tax law.
An exercise price is the price at which the holder of a call option has the right, but not the obligation, to purchase shares of a particular underlying stock by the expiration date.
SEC selling fees will quadruple on 5/14/2022 from sec.gov
Consequently, each SRO will continue to pay the Commission a rate of $5.10 per million for covered sales occurring on charge dates through May 13, 2022, and a rate of $22.90 per million for covered sales occurring on charge dates on or after May 14, 2022.